Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first‐line therapies
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: We aimed to assess the treatment response of infantile-onset epileptic spasms (ES) in CDKL5 deficiency disorder (CDD) vs other etiologies. METHODS: We evaluated patients with ES from the CDKL5 Centers of Excellence and the National Infantile Spasms Consortium (NISC), with onset from 2 months to 2 years, treated with adrenocorticotropic hormone (ACTH), oral corticosteroids, vigabatrin, and/or the ketogenic diet. We excluded children with tuberous sclerosis complex, trisomy 21, or unknown etiology with normal development because of known differential treatment responses. We compared the two cohorts for time to treatment and ES remission at 14 days and 3 months. RESULTS: We evaluated 59 individuals with CDD (79% female, median ES onset 6 months) and 232 individuals from the NISC database (46% female, median onset 7 months). In the CDD cohort, seizures prior to ES were common (88%), and hypsarrhythmia and its variants were present at ES onset in 34%. Initial treatment with ACTH, oral corticosteroids, or vigabatrin started within 1 month of ES onset in 27 of 59 (46%) of the CDD cohort and 182 of 232 (78%) of the NISC cohort (p < .0001). Fourteen-day clinical remission of ES was lower for the CDD group (26%, 7/27) than for the NISC cohort (58%, 106/182, p = .0002). Sustained ES remission at 3 months occurred in 1 of 27 (4%) of CDD patients vs 96 of 182 (53%) of the NISC cohort (p < .0001). Comparable results were observed with longer lead time (≥1 month) or prior treatment. Ketogenic diet, used within 3 months of ES onset, resulted in ES remission at 1 month, sustained at 3 months, in at least 2 of 13 (15%) individuals with CDD. SIGNIFICANCE: Compared to the broad group of infants with ES, children with ES in the setting of CDD often experience longer lead time to treatment and respond poorly to standard treatments. Development of alternative treatments for ES in CDD is needed.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first‐line therapies
- Date Crossref
- 15/05/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Boston Children's Hospital Department of Neurology pays non établi dans la noticeÉtablissement de santé
-
Children's Hospital Colorado pays non établi dans la noticeÉtablissement de santé
-
University of Colorado Anschutz pays non établi dans la noticeUniversité ou école supérieure
-
University of Colorado Denver pays non établi dans la noticeUniversité ou école supérieure
-
Cleveland Clinic Epilepsy Center pays non établi dans la noticeÉtablissement de santé
-
Washington University in St. Louis pays non établi dans la noticeUniversité ou école supérieure
-
Children's Hospital of Philadelphia pays non établi dans la noticeOrganisme public
-
University of Pennsylvania Children's Hospital of Philadelphia pays non établi dans la noticeUniversité ou école supérieure
-
Mattel Children's Hospital Division of Pediatric Neurology pays non établi dans la noticeÉtablissement de santé
-
Baylor College of Medicine Department of Pediatrics and Neurology pays non établi dans la noticeUniversité ou école supérieure
-
Texas Children's Hospital pays non établi dans la noticeOrganisme public
-
Harvard University pays non établi dans la noticeUniversité ou école supérieure
Department of Neurology — Boston Children's Hospital, Children's Hospital Colorado et University of Colorado Anschutz, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.